We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also, if the EKF spin-out of RENX is anything to go by, shares in ZAK will be allocated on a pro-rata basis to your holding in SCLP at the time of the announcement. Not a time for selling now...!
I see the new company as a hugely positive step. I've been in EKF Diagnostics (EKF)or a few years and they spun off part of their technology into a JV, Renalytx Ai, listed separately as RENX. As a result, I got free shares in RENX ( which have surged since) while the 'parent' EKF have tripled in value. I will be more than happy if Scancell and their new baby, Zakari, do the same!!
GLA.
Agree GF. Hanging onto my hat just in case there is an acceleration.
Miavoce,
As you say there are a few spin offs but often that is disposal of a non core asset and the easiest part of the franchise to consider separate developments for are either Covidity or the mAB side.
But even those have IP links via Immunobody and Avidmab to the core platform of cancer Vaccines.
So whilst good to speculate we simply don’t know and there are lots of reasons why SCLP may want to set up a separate Company and good to see it includes the whole of the BoD and I only see it as a positive sign but would like to know more about the strategy behind it.
You may be right re disposal of non core assets like many of other spin outs but no matter as we have to have confidence in the BoD making the right decision and SCLP retain total ownership.
If it Is a spin off say then this will realise greater value to SH than keeping it in house and that has to be of benefit to SH but clarification would be helpful.
Surprised CH did not appear on any media yesterday so perhaps there may be more news due which merits an sppearance
Chester.
My comment on this is that you can license via main co. But if you partner you could effectively allow a third party to “buy in” to the subsidiary for a cash value and then progress the product in that JV co and share future revenues in accordance with % ownership.
I think it’s a JV vehicle for a deal that is probably not far off. Otherwise why set it up and sit on it to then try and put the strategy in place?
No more likely IMO that the strategy and agreement is close and needs a JV co to exist to execute. Just my view but I suspect it won’t be long before we know.
I suspect some may inject confusion and attempt sinister reasons for new subsidiary but Sclp own 100% of it and any additional shares will be issued for some kind of consideration and as such I can only see this as positive for current Sclp share owners.
ATB
Many Thanks Chester and Mia.
Morning BOJO
My initial thoughts were that it was to hive off one of the platforms and I wrongly feared that would be to our detriment.
However, having calmed down and been given explanations by Berm and GF it is correct to assume it is to allow for deals, licences or partnerships, possibly on this occasion solely for the Glycan Mabs platform.
It will be wholely owned subsidiary of Scancell Limited which intern is wholely owned by Scancell Holdings PLC, where our shares reside.
The science and IP owned by Scancell has so much potential value that this may be just the start of separating out the different elements making the process of out licencing and partnerships much less messy.
Chester.
Hi BOJO
as we the shareholders own Zakari (by virtue of us owning Scancell) then if Zakari is spun out we still own it. Depending on how the spin out is done we may be allotted shares in Zakari directly, or shares would be allotted to Scancell (and therefore increase the value of Scancell). If Zakari then issue further shares to raise funds the % of Zakari that we hold (directly or via Scancell) would decrease but Zakari would have the funds needed to develop the mAbs which should increase the overall value of Zakari.
As spin outs are seemingly common in this sector, would it be worth buying shares in a spin out?
What benefit would a shareholder of the main holding get (value).
Do we see Zakari as a spin out?
Thanks.